Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp.

MDNAF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$21.11M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Medicenna Therapeutics Corp.Medicenna Therapeutics Corp.-1.7--60%-0.2

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$21.11 Million
Enterprise Value$-880,094.00
Earnings per Share$-
Beta2.09
Outstanding Shares0

Return

Return on Equity-60.05%ROE
Return on Assets-50.73%
Return on Invested Capital-93.91%

Valuation & Multiples

P/E Ratio-1.75P/E Ratio
PEG-0.69PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT0.04
Enterprise Value to Net Income0
Total Debt to Enterprise-4.2
Debt to Equity0.16Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 16, 2026
EPS
-$0.03
Est. -$0.04
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
February 11, 2027
EPS Estimate
-$0.03
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Medicenna Therapeutics Corp

20 employees
CEO: Fahar Merchant

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It dev...

Questions & Answers